The European Commission has approved SKYRIZI (risankizumab) for treating moderate to severe plaque psoriasis in children and adolescents aged six and older. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing in patients under 40 kg. The decision is based on positive results from Phase 3 OptIMMize trials showing safety and efficacy consistent with adult patients. This expands treatment options for pediatric psoriasis, a condition affecting nearly a third of patients before age 18, often impacting visible areas and quality of life.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
